Lantern Pharma (NASDAQ:LTRN) Director Purchases $100,000.64 in Stock

Lantern Pharma Inc. (NASDAQ:LTRN) Director Lee Troy Schalop purchased 48,544 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was bought at an average cost of $2.06 per share, for a total transaction of $100,000.64. Following the purchase, the director owned 48,544 shares in the company, valued at $100,000.64. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Lantern Pharma Price Performance

Shares of LTRN stock opened at $3.14 on Friday. The stock’s fifty day simple moving average is $2.22 and its 200 day simple moving average is $2.92. The firm has a market cap of $35.51 million, a price-to-earnings ratio of -2.17 and a beta of 2.10. Lantern Pharma Inc. has a one year low of $1.11 and a one year high of $5.74.

Lantern Pharma (NASDAQ:LTRN) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Weiss Ratings raised Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 7th. Wall Street Zen raised Lantern Pharma to a “sell” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Lantern Pharma currently has an average rating of “Sell”.

Hedge Funds Weigh In On Lantern Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd bought a new stake in shares of Lantern Pharma during the second quarter worth $40,000. Vanguard Group Inc. raised its position in shares of Lantern Pharma by 5.6% during the third quarter. Vanguard Group Inc. now owns 384,041 shares of the company’s stock worth $1,671,000 after acquiring an additional 20,321 shares during the last quarter. CM Management LLC raised its position in shares of Lantern Pharma by 12.5% during the third quarter. CM Management LLC now owns 225,000 shares of the company’s stock worth $979,000 after acquiring an additional 25,000 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Lantern Pharma during the third quarter worth $70,000. Finally, Susquehanna International Group LLP bought a new stake in shares of Lantern Pharma during the third quarter worth $170,000. Institutional investors and hedge funds own 28.62% of the company’s stock.

Lantern Pharma Company Profile

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.